Evidence map›Paper›PMID 41732517›Full record

ArticleTherapeutic advances in endocrinology and metabolism2026

Use of serum MKRN3 and DLK1 levels in precocious puberty: association with an MKRN3 pathogenic variant.

Esin Karakilic-Ozturan, Volkan Karaman, Asuman Gedikbaşı, Şükran Poyrazoğlu, Feyza Darendeliler, Zehra Oya Uyguner, Firdevs Baş

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Esin Karakilic-OzturanDepartment of Pediatric Endocrinology and Diabetes, Istanbul Faculty of Medicine, Istanbul University, Istanbul 34093, Türkiye.ORCID https://orcid.org/0000-0002-8842-1752
Volkan KaramanDepartment of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Asuman GedikbaşıDepartment of Pediatric Basic Sciences, Institute of Child Health, Istanbul University, Istanbul, Türkiye.
Şükran PoyrazoğluDepartment of Pediatric Endocrinology and Diabetes, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Feyza DarendelilerDepartment of Pediatric Endocrinology and Diabetes, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Zehra Oya UygunerDepartment of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Firdevs BaşDepartment of Pediatric Endocrinology and Diabetes, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Loss-of-function alterations in Objectives: This study aimed to evaluate the potential of serum MKRN3 and DLK1 levels for predicting genetic variants associated with CPP. Design: Retrospective study. Methods: This retrospective cross-sectional study included 26 girls with CPP: 11 receiving treatment (Group 1) and 15 not yet treated (Group 2). The control group consisted of 26 healthy girls. Serum MKRN3 and DLK1 levels were measured by ELISA, and Results: A known pathogenic Conclusion: MKRN3 and DLK1 levels do not significantly differ between treated, untreated CPP patients, and healthy controls. Identifying a known

Indexed as

central precocious pubertyDLK1MKRN3serum level

Identifiers

PMID41732517
PMCPMC12924910

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.